These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19078483)

  • 1. Desensitization to allopurinol after allopurinol hypersensitivity syndrome with renal involvement in gout.
    Vázquez-Mellado J; Vázquez SG; Barrientos JC; Ríos VG; Burgos-Vargas R
    J Clin Rheumatol; 2000 Oct; 6(5):266-8. PubMed ID: 19078483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypersensitivity to Febuxostat in a Patient with a Previous Allopurinolinduced Steven-Johnson Syndrome: A Case Report of Treatment with a Slow Desensitization Protocol.
    Calogiuri G; Congedo M; Nettism E; Macchia L; Foti C; Vacca A
    Endocr Metab Immune Disord Drug Targets; 2022; 22(8):895-899. PubMed ID: 35379143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [De-sensitization to allopurinol in a patient with tophi gout].
    López-Rocha EG; Hernández-Montoya G; Rodríguez-Pesina AH; Rodríguez-Mireles KA
    Rev Alerg Mex; 2018; 65(3):316-320. PubMed ID: 30176211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allopurinol desensitization with A 2 weeks modified protocol in an elderly patients with multiple comorbidities: a case report.
    Dursun AB; Sahin OZ
    Allergy Asthma Clin Immunol; 2014; 10(1):52. PubMed ID: 25685161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skin rash, eosinophilia, and renal impairment in a patient recently started on allopurinol.
    Jmeian A; Hawatmeh A; Shamoon R; Shamoon F; Guma M
    J Family Med Prim Care; 2016; 5(2):479-481. PubMed ID: 27843869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allopurinol sensitivity in a patient with chronic tophaceous gout: success of intravenous desensitization after failure of oral desensitization.
    Walz-LeBlanc BA; Reynolds WJ; MacFadden DK
    Arthritis Rheum; 1991 Oct; 34(10):1329-31. PubMed ID: 1930322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desensitization to allopurinol in patients with gout and cutaneous reactions.
    Fam AG; Lewtas J; Stein J; Paton TW
    Am J Med; 1992 Sep; 93(3):299-302. PubMed ID: 1388001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of desensitization to allopurinol following cutaneous reactions.
    Fam AG; Dunne SM; Iazzetta J; Paton TW
    Arthritis Rheum; 2001 Jan; 44(1):231-8. PubMed ID: 11212165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A case of vanishing bile duct syndrome associated with hypersensitivity to allopurinol].
    Choi SH; Yang SH; Song YB; Kim HJ; Seo YT; Choi DS; Moon KH; Byun JH; Yu ES
    Korean J Hepatol; 2005 Mar; 11(1):80-5. PubMed ID: 15788888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal allopurinol-induced hypersensitivity syndrome associated with pancreatic abnormalities.
    Fathallah N; Ben Salem C; Slim R; Kaabia N; Letaief A; Bouraoui K
    J Clin Rheumatol; 2010 Jun; 16(4):170-1. PubMed ID: 20511977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allopurinol-induced severe hypersensitivity with acute renal failure.
    Chen IH; Kuo MC; Hwang SJ; Chang JM; Chen HC
    Kaohsiung J Med Sci; 2005 May; 21(5):228-32. PubMed ID: 15960069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan.
    Yang CY; Chen CH; Deng ST; Huang CS; Lin YJ; Chen YJ; Wu CY; Hung SI; Chung WH
    JAMA Intern Med; 2015 Sep; 175(9):1550-7. PubMed ID: 26193384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desensitization to allopurinol in a patient with previous failed desensitization.
    Tanna SB; Barnes JF; Seth SK
    Ann Pharmacother; 1999 Nov; 33(11):1180-3. PubMed ID: 10573316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The efficacy and tolerability of allopurinol dose escalation in patients with gout].
    Radak-Perović M; Zlatković-Svenda M
    Srp Arh Celok Lek; 2013; 141(5-6):333-6. PubMed ID: 23858803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous desensitization to allopurinol in a heart transplant patient with gout.
    Schumacher MJ; Copeland JG
    Ann Allergy Asthma Immunol; 2004 Mar; 92(3):374-6. PubMed ID: 15049403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
    Becker MA; Fitz-Patrick D; Choi HK; Dalbeth N; Storgard C; Cravets M; Baumgartner S
    Semin Arthritis Rheum; 2015 Oct; 45(2):174-83. PubMed ID: 26190562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allopurinol-induced DRESS syndrome.
    Yaylacı S; Demir MV; Temiz T; Tamer A; Uslan MI
    Indian J Pharmacol; 2012 May; 44(3):412-4. PubMed ID: 22701258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation between adverse events associated with allopurinol and renal function in patients with gout.
    Vázquez-Mellado J; Morales EM; Pacheco-Tena C; Burgos-Vargas R
    Ann Rheum Dis; 2001 Oct; 60(10):981-3. PubMed ID: 11557658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
    Dalbeth N; Kumar S; Stamp L; Gow P
    J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.
    Stamp LK; Taylor WJ; Jones PB; Dockerty JL; Drake J; Frampton C; Dalbeth N
    Arthritis Rheum; 2012 Aug; 64(8):2529-36. PubMed ID: 22488501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.